Tuesday, 20 August 2019

Clinigen K.K., GC Pharma sign pact to market Hunterase ICV

05 April 2019 | News

Hunterase (Idursulfase-beta) ICV, a human recombinant iduronate-2-sulfatase (IDS) used in enzyme replacement therapy for the treatment of Hunter syndrome

Clinigen K.K. and GC Pharma have recently announced an exclusive licensing agreement in Japan to commercialize Hunterase (Idursulfase-beta) ICV, a human recombinant iduronate-2-sulfatase (IDS) used in enzyme replacement therapy for the treatment of Hunter syndrome. Used as one of the methods for Hunter syndrome treatment, intravenous injection does not penetrate the blood brain barrier in clinically adequate amounts.

Hunterase (Idursulfase-beta) ICV developed by GC Pharma is delivered directly to cerebral ventricles by intracerebroventricular (ICV) administration, in order to reach the cells of the brain and central nervous system.

Hunterase (Idursulfase-beta) ICV is expected to meet the unmet needs of severe patients in improving their quality of life, as a method that can achieve what previous intravenous injection could not. The Phase 1/2 clinical trial conducted as an investigator-initiated trial by Prof. Torayuki Okuyama in National Center for Child Health and Development in Japan showed a significant decrease in Heparan sulfate which causes mental retardation.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Will APAC lead the way for innovation in the field of precision medicine?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls